Rahman Ravelli
Rahman Ravelli Solicitors Logo
Rapid Response Team: 0800 559 3500
Switchboard: +44 (0)203 947 1539

About Us Expertise PEOPLE International Legal Articles News Events Contact Us toggle button for phone toggle button for search
Rapid Response Team: 0800 559 3500
Switchboard: +44 (0)203 947 1539
search
Rapid Response Team: 0800 559 3500
Switchboard: +44 (0)203 947 1539
search

Shares of pharmaceutical giant Valeant have been falling after a research firm accused it of large-scale fraud

Author: Nicola Sharp  5 November 2015

Federal prosecutors were already probing the way the Canadian company prices and distributes its drugs. Now Citron, a firm that actively bets against stocks and publishes negative research on companies, is claiming that Valeant could be the “pharmaceutical Enron.”

Citron believes a “web of deception” has involved creating “invoices to deceive auditors and book revenue.” Valeant has said the claims are erroneous, false and misleading and intended to manipulate the market.

The only way this can be settled is by investigators trawling through the masses of documentation available. It will then be an issue of who can make the strongest case from the evidence at their disposal.

Nicola Sharp C 09983

Nicola Sharp

Partner

nicola.sharp@rahmanravelli.co.uk
+44 (0)203 910 4567 vCard

Download Profile PDF

View Profile

Nicola is known for her fraud, civil recovery, arbitration and business crime expertise, her experience of leading the largest financial disputes and multinational investigations and her skills in devising preventative measures and conducting internal investigations for corporates.

Share this article on